Patents by Inventor Anand A. Natrajan

Anand A. Natrajan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11932603
    Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: March 19, 2024
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Sharpe, Qingping Jiang, David Wen
  • Publication number: 20220227711
    Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.
    Type: Application
    Filed: April 7, 2022
    Publication date: July 21, 2022
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Sharpe, Qingping Jiang, David Wen
  • Patent number: 11332445
    Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: May 17, 2022
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Sharpe, Qingping Jiang, David Wen
  • Publication number: 20220073468
    Abstract: The present invention provides compounds used in the synthesis of chemiluminescent acridinium compounds and methods of producing these compounds. Specifically, methods are provided for the N-alkylation of acridan compounds using alkylating reagents. Typically, these alkylating reagents comprise a protected sulfonate group protected with an acid-labile protecting group.
    Type: Application
    Filed: November 15, 2021
    Publication date: March 10, 2022
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventor: Anand Natrajan
  • Patent number: 11203573
    Abstract: The present invention provides compounds used in the synthesis of chemiluminescent acridinium compounds and methods of producing these compounds. Specifically, methods are provided for the N-alkylation of acridan compounds using alkylating reagents. Typically, these alkylating reagents comprise a protected sulfonate group protected with an acid-labile protecting group.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: December 21, 2021
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventor: Anand Natrajan
  • Publication number: 20210230119
    Abstract: The present invention provides compounds used in the synthesis of chemiluminescent acridinium compounds and methods of producing these compounds. Specifically, methods are provided for the N-alkylation of acridan compounds using alkylating reagents. Typically, these alkylating reagents comprise a protected sulfonate group protected with an acid-labile protecting group.
    Type: Application
    Filed: June 25, 2019
    Publication date: July 29, 2021
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventor: Anand Natrajan
  • Patent number: 10859504
    Abstract: The present invention relates to methods of enhancing chemiluminescence from a chemiluminescent label comprising contacting a chemiluminescent label with an acid in the presence of a degradable cationic surfactant and hydrogen peroxide followed by the addition of a base. Related kits containing such degradable cationic surfactant are also provided. The degradable cationic surfactant can compress light emission time of the chemiluminescent label to an extent that is comparable to or shorter than conventional surfactants. The degradable cationic surfactant can also increase chemiluminescence of the chemiluminescent label, providing increased light emission output that is comparable to conventional surfactants.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: December 8, 2020
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Wen
  • Patent number: 10710962
    Abstract: Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules.
    Type: Grant
    Filed: May 28, 2016
    Date of Patent: July 14, 2020
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Sharpe, David Wen, Qingping Jiang
  • Publication number: 20200190037
    Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Sharpe, Qingping Jiang, David Wen
  • Publication number: 20190234883
    Abstract: The present invention relates to methods of enhancing chemiluminescence from a chemiluminescent label comprising contacting a chemiluminescent label with an acid in the presence of a degradable cationic surfactant and hydrogen peroxide followed by the addition of a base. Related kits containing such degradable cationic surfactant are also provided. The degradable cationic surfactant can compress light emission time of the chemiluminescent label to an extent that is comparable to or shorter than conventional surfactants. The degradable cationic surfactant can also increase chemiluminescence of the chemiluminescent label, providing increased light emission output that is comparable to conventional surfactants.
    Type: Application
    Filed: September 7, 2018
    Publication date: August 1, 2019
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Wen
  • Patent number: 10073039
    Abstract: The present invention relates to methods of enhancing chemiluminescence from a chemiluminescent label comprising contacting a chemiluminescent label with an acid in the presence of a degradable cationic surfactant and hydrogen peroxide followed by the addition of a base. Related kits containing such degradable cationic surfactant are also provided. The degradable cationic surfactant can compress light emission time of the chemiluminescent label to an extent that is comparable to or shorter than conventional surfactants. The degradable cationic surfactant can also increase chemiluminescence of the chemiluminescent label, providing increased light emission output that is comparable to conventional surfactants.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: September 11, 2018
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS, INC.
    Inventors: Anand Natrajan, David Wen
  • Publication number: 20170320830
    Abstract: Hydrophilic, high quantum yield, chemiluminescent acridinium compounds with increased light output, improved stability, fast light emission and decreased non specific binding are disclosed. The chemiluminescent acridinium esters possess hydrophilic, branched, electron-donating functional groups at the C2 and/or C7 positions of the acridinium nucleus.
    Type: Application
    Filed: July 4, 2014
    Publication date: November 9, 2017
    Inventors: Anand Natrajan, David Sharpe, Qingping Jiang, David Wen
  • Patent number: 9575062
    Abstract: Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: February 21, 2017
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Anand Natrajan, David Sharpe, Qingping Jiang
  • Patent number: 9512080
    Abstract: A method is provided for N-alkylation of acridine compounds by reduction of acridines to corresponding acridans to improve the reactivity of the acridine nitrogen, and subsequent N-alkylation of the acridans in ionic liquid solvents to provide the corresponding acridinium compounds in high yield. This inventive process improves chemical conversion, and does not require the use of highly toxic alkylating agents, such as 1,3-propane sultone.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: December 6, 2016
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Anand Natrajan, David Wen
  • Patent number: 9487480
    Abstract: Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: November 8, 2016
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Sharpe, David Wen, Qingping Jiang
  • Publication number: 20160274094
    Abstract: Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules.
    Type: Application
    Filed: May 28, 2016
    Publication date: September 22, 2016
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Sharpe, David Wen, Qingping Jiang
  • Patent number: 9353056
    Abstract: Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: May 31, 2016
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Sharpe, David Wen, Qingping Jiang
  • Publication number: 20160131588
    Abstract: The present invention relates to methods of enhancing chemiluminescence from a chemiluminescent label comprising contacting a chemiluminescent label with an acid in the presence of a degradable cationic surfactant and hydrogen peroxide followed by the addition of a base. Related kits containing such degradable cationic surfactant are also provided. The degradable cationic surfactant can compress light emission time of the chemiluminescent label to an extent that is comparable to or shorter than conventional surfactants. The degradable cationic surfactant can also increase chemiluminescence of the chemiluminescent label, providing increased light emission output that is comparable to conventional surfactants.
    Type: Application
    Filed: May 13, 2014
    Publication date: May 12, 2016
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Wen
  • Publication number: 20150197491
    Abstract: A method is provided for N-alkylation of acridine compounds by reduction of acridines to corresponding acridans to improve the reactivity of the acridine nitrogen, and subsequent N-alkylation of the acridans in ionic liquid solvents to provide the corresponding acridinium compounds in high yield. This inventive process improves chemical conversion, and does not require the use of highly toxic alkylating agents, such as 1,3-propane sultone.
    Type: Application
    Filed: July 10, 2013
    Publication date: July 16, 2015
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Wen
  • Publication number: 20140295575
    Abstract: Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity.
    Type: Application
    Filed: June 11, 2014
    Publication date: October 2, 2014
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Anand Natrajan, David Sharpe, Qingping Jiang